Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{179498,
        author = {Monika Sharma and Pranjali Mishra},
        title = {BREAST CANCER},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {1},
        pages = {3765-3767},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=179498},
        abstract = {Breast cancer is a malignant disease originating in breast tissue, primarily affecting women but also occurring in men. It commonly begins in the ducts (ductal carcinoma) or lobules (lobular carcinoma) of the breast. Breast cancer is categorized into non-invasive (in situ) and invasive types, with invasive ductal carcinoma being the most prevalent, accounting for 70–80% of cases. Risk factors encompass genetic mutations (e.g., BRCA1/BRCA2), hormonal influences, lifestyle choices, and family history. Early detection through regular screening, such as mammography, significantly enhances treatment outcomes. Treatment modalities include surgery, radiation therapy, chemotherapy, hormone therapy, and targeted biological therapies. Advancements in medical research continue to improve prognosis and survival rates for breast cancer patients},
        keywords = {Breast cancer, Ductal carcinoma in situ (DCIS), Lobular carcinoma in situ (LCIS), Invasive ductal carcinoma (IDC), Invasive lobular carcinoma (ILC), BRCA1/BRCA2 mutations, Hormone receptor-positive breast cancer},
        month = {June},
        }